SAM
TGTX icon

Silphium Asset Management’s TG Therapeutics TGTX Stock Holding History

Silphium Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-20,000
Closed -$188K – 87
2014
Q2 		$188K Buy
+20,000
New +$128K 0.13% 86

Other funds holding TGTX

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silphium Asset Management's TGTX Position: Q3 2014 in Review

Silphium Asset Management sold out of TG Therapeutics (TGTX) in Q3 2014, closing a stake of 20,000 shares — an estimated $188K sold.

Silphium Asset Management first reported a position in TGTX in Q2 2014 and held it in 1 quarter. The position peaked at $188K in Q2 2014. 66 funds tracked by Wall St. Rank hold TGTX as of Q3 2014.

  • Silphium Asset Management reported no remaining TG Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Silphium Asset Management sold 20,000 TG Therapeutics shares in Q3 2014, an estimated $188K.
  • Silphium Asset Management first reported a position in TG Therapeutics in Q2 2014 and held it in 1 quarter.
  • Silphium Asset Management's TG Therapeutics position peaked at $188K in Q2 2014.
  • 66 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2014.

Based on Silphium Asset Management's 13F filing for Q3 2014, filed 30 Jan 2025.